On April 9, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, reported that it will have multiple oral and poster presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting being held April 17-22, 2026, in San Diego, California. New preclinical data for Selective SMARCA2 inhibitor FHD-909 will be featured as part of an oral presentation and preclinical data for Selective CBP, Selective EP300, and Selective ARID1B degrader programs will be featured as poster presentations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"FHD-909 is advancing in the clinic in collaboration with Lilly as the first potential selective SMARCA2 inhibitor for the treatment of SMARCA4-mutant cancers. We are excited to present new, compelling preclinical data further supporting potential expansion opportunities in combination with an anti-PD-1 antibody, as part of Dr. Bellon’s oral presentation at this year’s AACR (Free AACR Whitepaper)," said Adrian Gottschalk, President, and Chief Executive Officer of Foghorn. "Poster presentations will also highlight additional preclinical data characterizing our wholly owned Selective CBP, Selective EP300, and Selective ARID1B degrader programs. Collectively, these data underscore the differentiated profiles of our pipeline programs which may translate to improved therapeutic outcomes for difficult to treat cancers with significant unmet need."
Oral Presentation Details
Title: Targeting chromatin regulatory proteins in hematologic malignancies
Town Meeting: Chemistry, Hematologic Malignancies – From Molecules to Medicine – Driving Breakthroughs in Blood Cancer Treatment: A CICR-HMWG Town Hall
Session Date/Time: Monday, April 20, 6:30 p.m. – 8:30 p.m. PDT
Presenter: Gromek Smolen, VP, Biology, Foghorn Therapeutics
Title: Leveraging paralog relationships for targeting chromatin modulators in cancer: ARID1B and SMARCA2 (FHD-909)
Session: Molecular/Cellular Biology and Genetics, Chemistry, Drug Development – Synthetic Lethality in Oncology: Progress Made, Pitfalls Encountered, and the Path Forward
Session Date/Time: Tuesday, April 21, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Steven Bellon, Chief Scientific Officer, Foghorn Therapeutics
Title: Towards new cancer medicines with degraders of chromatin regulatory proteins
Session: Chemistry, Drug Development, Experimental and Molecular Therapeutics – Induced Proximity Pharmacology: Degraders and Beyond
Session Date/Time: Wednesday, April 22, 10:15 a.m. – 11:45 a.m. PDT
Presenter: Danette Daniels, VP, Degrader Platform, Foghorn Therapeutics
Poster Presentation Details
Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies
Session: Experimental and Molecular Therapeutics – Quantitative Pharmacology and Translational Modeling
Poster Number: 1828 / 16
Session Date/Time: Monday, April 20, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Meiyun Lin, Senior Scientist, Pharmacology, Foghorn Therapeutics
Abstract: Click here
Title: Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity
Session: Chemistry – Targeted Protein Degradation and Induced Proximity
Poster Number: 5163 / 13
Session Date/Time: Tuesday, April 21, 9:00 a.m. – 12:00 p.m. PDT
Presenter: Karolina Mizeracka, Principal Scientist, Cell Biology, Foghorn Therapeutics
Abstract: Click here
Title: Identification of first-in-class selective ARID1B degraders
Session: Experimental and Molecular Therapeutics – Proximity-Induced Drug Discovery 2
Poster Number: 5792 / 19
Session Date/Time: Tuesday, April 21, 2:00 p.m. – 5:00 p.m. PDT
Presenter: Madeleine Henley, Senior Scientist, Foghorn Therapeutics
Abstract: Click here
Title: Preclinical characterization of FHT-171, a first-in-class degrader targeting CREB-binding protein (CBP) in CBP-dependent solid tumors
Session: Experimental and Molecular Therapeutics – Epigenetic Modulators 2
Poster Number: 7075 / 22
Session Date/Time: Wednesday, April 22 9:00 a.m. – 12:00 p.m. PDT
Presenter: Darshan Sappal, Director, Biology, Foghorn Therapeutics
Abstract: Click here
Dr. Bellon’s presentation and the posters will be accessible under the Science section of the Company’s website.
(Press release, Foghorn Therapeutics, APR 9, 2026, View Source [SID1234664291])